Main Article Content
After recalling that Levonorgestrel Emergency Contraceptive Pills never delay or suppress ovulation, but impair the luteal body functions, and, consequently, the embryo-implantation, we focus on the mechanism of action (MOA) of ellaOne®: micronized UPA (Ulipristal Acetate) 30mg and on UPA- toxicity.
EMA and, after it, the National Drug Regulatory Institutions and the most renowned International Gynecological Societies present ellaOne® as an anti-ovulatory drug which is safe even in repeated assumption, also during the same menstrual cycle. We’ll try to understand whether this dogma is supported by experimental data in literature.
As to the MOA, EMA reports (EMEA-261787-2009) that Ulipristal blocks the synthesis of the proteins necessary to begin and maintain pregnancy, and that Ulipristal and mifepristone were approximately equipotent as to their ability to terminate pregnancy. Besides, EMA further evidences (EMA/73099/2015) that it is unknown whether it is possible to use ellaOne® for abortion.
Data in Literature evidence that ellaOne® can delay ovulation only when is taken in the very first fertile days of the cycle. In the pre-ovulatory, most fertile, days - when most intercourses do occur and over 70% fertilizations ensue - it never prevents ovulation, like placebo. On the contrary, whenever it is taken in the cycle, it consistently impairs the endometrium that becomes an inhospitable ground for the embryo: endometrial gene expression is completely subverted compared with that of the normal luteal phase.
Recently, an UPA-based drug used for uterine fibroids-treatment (Esmya®) was withdrawn from the market because it caused fulminant hepatitis requiring transplantation (EMA/455818/2020). It was prescribed by the hospital for 3-6 months and carefully followed-up. The strict post-marketing surveillance allowed to link UPA-administration and tissue-accumulation to liver-failure. Surprisingly EMA, while revoking Esmya®, warranted for the safety of ellaOne®, though it is taken by millions of women unaware of the risk, repeatedly without prescription, without medical supervision and any possibility of post-marketing surveillance, in UPA-cumulating doses even greater than with Esmya®.
Finally, we criticize the attempt to propose UPA in daily contraceptive pills, at doses even double than in Esmya® and for much longer periods, to fertile women aiming at preserving their fertility and health.
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
2. Wilcox AJ, Baird DD, Dunson DB, et al. On the frequency of intercourse around ovulation: evidence for biological influences. Hum Reprod. 2004;19:1539-1543.
3. Dunson DB, Baird DD, Wilcox AJ, et al. Day-specific probabilities of clinical pregnancy based on two studies with imperfect measures of ovulation. Hum Reprod. 1999;14:1835-1839.
4. Behre HM, Kulhage J, Gassner C, et al. Prediction of ovulation by urinary hormone measurements with the home use ClearPlan Fertility Monitor: comparison with transvaginal ultrasound scans and serum hormone measurements. Hum Reprod. 2000;15:2478-2482.
5. Fine P, Mathé H, Ginde S, et al. Ulipristal acetate taken 48-120 hours after intercourse for emergency contraception. Obstet Gynecol. 2010;115:257-263.
6. Stirling A, Glasier A. Estimating the efficacy of emergency contraception—how reliable are the data? Contraception. 2002;66:19-22.
7. Dye HM, Stanford JB, Alder SC, et al. Women and postfertilization effects of birth control: consistency of beliefs, intentions and reported use. BMC Womens Health. 2005;5:11.
8. de Irala J, Lopez del Burgo C, Lopez de Fez CM, et al. Women's attitudes towards mechanisms of action of family planning methods: survey in primary health centres in Pamplona, Spain. BMC Womens Health. 2007;7:10.
9. Campbell JW 3rd, Busby SC, Steyer TE. Attitudes and beliefs about emergency contraception among patients at academic family medicine clinics. Ann Fam Med. 2008;6 Suppl 1:S23-27.
10. Lopez-del Burgo C, Lopez-de Fez CM, Osorio A, Guzmán JL, et al. Spanish women's attitudes towards post-fertilization effects of birth control methods. Eur J Obstet Gynecol Reprod Biol. 2010;151(1):56-61.
11. World Health Organization (WHO) Media centre. Emergency contraception: Fact sheet. [Reviewed 2018 February]. http://www.who.int/ [Internet] Available from: http://www.who.int/mediacentre/factsheets/fs244/en/.
12. Advisory Committee for Reproductive Health Drugs. Ulipristal acetate 30 mg tablet.– Briefing Materials. 2010 June 17. http://www.accessdata.fda.gov/ [Internet] Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reprductivehealthdrugsadvisorycommittee/ucm215510.pdf.
13. Watson Medical Communication. Highlights of Prescribing Information - Ella Tablet. 2010 October. http://www.accessdata.fda.gov/ Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022474s000lbl.pdf.
14. European Medicines Agency (EMA). European Public Assessment Report (EPAR) on ellaOne [updated 16/11/2022. https://www.ema.europa.eu/en/documents/product-information/ellaone-epar-product-information_en.pdf.
15. International Federation of Gynecology & Obstetrics (FIGO) and International Consortium for Emergency Contraception (ICEC). How do Levonorgestrel-only emergency contraceptive pills (LNG ECPs) work to prevent pregnancy?; 2012 March. http://www.cecinfo.org/ Available from: http://www.cecinfo.org/custom-content/uploads/2014/01/ICEC_MoA_Statement_3-28-12.pdf .
16. Mozzanega B, Cosmi E. How do levonorgestrel-only emergency contraceptive pills prevent pregnancy? Some considerations. Gynecological Endocrinology. 2011;27:439-442.
17. Peck R, Rella E, Tudela J, Aznar J, Mozzanega B. Does levonorgestrel emergency contraceptive have a post-fertilization effect? A review of its mechanism of action. The Linacre Quarterly. 2016;83(1):35-51, doi/full/10.1179/2050854915Y.0000000011.
18. Mozzanega B, Nardelli GB. UPA and LNG in Emergency Contraception: the information by EMA and the Scientific Evidences indicate a prevalent anti-implantation effect. Eur J Contracept Reprod Health Care. 2019;24(1):4-10. doi: 10.1080/13625187.2018.1555662. Epub 2019 Jan 18.
19. Marions L, Hultenby K, Lindell I, et al. Emergency contraception with mifepristone and levonorgestrel: mechanism of action. Obstet Gynecol. 2002;100:65-71.
20. Durand M, del Carmen Cravioto M, Raymond EG, et al. On the mechanisms of action of short-term levonorgestrel administration in emergency contraception. Contraception. 2001;64:227-234.
21. Hapangama D, Glasier AF, Baird DT. The effects of peri-ovulatory administration of levonorgestrel on the menstrual cycle. Contraception. 2001;64:123-129.
22. Okewole IA, Arowojolu AO, Odusoga OL, et al. Effect of single administration of levonorgestrel on the menstrual cycle. Contraception. 2007;75:372-377.
23. Durand M, Seppala M, Cravioto M, et al. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. Contraception. 2005;71:451-457.
24. The European Society of Contraception and Reproductive Health. How do Levonorgestrel-only emergency contraceptive pills (LNG ECPs) work to prevent pregnancy?; 2011 April 11. Available from: http://www.escrh.eu/about-esc/news/how-do-levonorgestrel.
25. Brache V, Cochon L, Jesam C, et al. Immediate pre-ovulatory administration of 30 mg ulipristal acetate significantly delays follicular rupture. Hum Reprod. 2010;25:2256-2263.
26. Croxatto HB, Brache V, Pavez M ey al. Pituitary-ovarian function following the standard levonorgestrel emergency contraceptive dose or a single 0.75-mg dose given on the days preceding ovulation. Contraception. 2004;70:442-450.
27. Massai MR, Forcelledo ML, Brache V, et al. Does meloxicam increase the incidence of anovulation induced by single administration of levonorgestrel in emergency contraception? A pilot study. Hum Reprod. 2007;22:434-439.
28. Brache V, Cochon L, Deniaud M, et al. Ulipristal acetate prevents ovulation more effectively than levonorgestrel: analysis of pooled data from three randomized trials of emergency contraception regimens. Contraception. 2013;88:611-618.
29. Noé G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulation. Contraception. 2010;81:414-420.
30. Glasier AF, Cameron ST, Fine PM, et al. Ulipristal acetate versus levonorgestrel for emergency contraception: a randomized non-inferiority trial and metaanalysis. Lancet. 2010;375(9714):555-562.
31. European Medicines Agency (EMA). CHMP Assessment Report for Ellaone - EMEA/H/C/001027. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/001027/WC500023673.pdf.
32. Tarantal AF, Hendrickx AG, Matlin SA, et al. Effects of Two Antiprogestins on Early Pregnancy in the Long-Tailed Macaque (Macaca fascicularis). Contraception. 1996;54:107-115.
33. European Medicines Agency (EMA). CHMP Assessment Report on ellaOne - EMA/73099/2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_Report_-_Variation/human/001027/WC500181904.pdf.
34. European Medicines Agency (EMA). Levonorgestrel and Ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight - EMA/631408/2014. http://www.ema.europa.eu/ Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Emergency_contraceptives_31/WC500176381.pdf
35. Jesam C, Cochon L, Salvatierra AM, Williams A, Kapp N, Levy-Gompel D, Brache V. A prospective, open-label, multicenter study to assess the pharmacodynamics and safety of repeated use of 30 mg ulipristal acetate. Contraception 2016;93:310–316. https://doi.org/10.1016/j. contraception.2015.12.015.
36. Gemzell-Danielsson K, Berger C, Lalitkumar PGL. Emergency contraception – mechanism of action. Contraception. 2013;87:300-308.
37. Lalitkumar PGL, Berger C, Gemzell-Danielsson K. Emergency contraception. Best Practice & Research Clinical Endocrinology & Metabolism. 2013;27:91-101.
38. Mozzanega B, Gizzo S, Di Gangi S, et al. Ulipristal Acetate: Critical Review About Endometrial and Ovulatory Effects in Emergency Contraception. Reprod Sci. 2014;21:678-685.
39. Lira-Albarrán S, Durand M, Larrea-Schiavon MF, et al. Ulipristal acetate administration at mid-cycle changes gene expression profiling of endometrial biopsies taken during the receptive period of the human menstrual cycle. Mol Cell Endocrinol. 2017;447:1-11.
40. Stratton P, Hartog B, Hajizadeh N, et al. A single mid-follicular dose of CDB-2914, a new antiprogestin, inhibits folliculogenesis and endometrial differentiation in normally cycling women. Hum Reprod. 2000;15:1092-1099.
41. Stratton P, Levens ED, Hartog B, et al. Endometrial effects of a single early luteal dose of the selective progesterone receptor modulator CDB-2914. Fertil Steril. 2010;93:2035-2041.
42. Passaro MD, Piquion J, Mullen N, et al. Luteal phase dose-response relationships of the antiprogestin CDB-2914 in normally cycling women. Hum Reprod. 2003;18:1820-1827.
43. Gemzell-Danielsson K, Rabe T, Cheng L. Emergency contraception. Gynecol Endocrinol 2013;29 (S1):1-14.
44. Gemzell-Danielsson K, Berger C, Lalitkumar PG. Mechanisms of action of oral emergency contraception. Gynecol Endocrinol 2014;30(10):685-687.
45. Li HWR, Resche-Rigon M, Bagchi IC, Gemzell-Danielsson K, Glasier A. Does ulipristal acetate emergency contraception (ella) interfere with implantation? Contraception 2019;100: 386–390.
46. Wagner BL, Polio G, Giangrande P, et al. The novel progesterone receptor antagonist RTI 3021-3012 and RTI 3021-3022 exhibit complex glucocorticoid receptor activities: implications for the development of dissociated antiprogestins. Endocrinology. 1999;140:1449-1458.
47. Blithe DL, Nieman LK, Blye RP, et al. Development of the selective progesterone receptor modulator CDB-2914 for clinical indications. Steroids. 2003;68:1013-1017.
48. Attardi BJ, Burgenson J, Hild SA, et al. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J Steroid Biochem Mol Biol. 2004;88:277-288.
49. Attardi BJ, Burgenson J, Hild SA, et al. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol Cell Endocrinol. 2002;188:111-123.
50. Gainer EE, Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids 2003;68:1005-11.
51. Rao PN, Wang Z, Cessac JW, et al. New 11beta-aryl-substituted steroids exhibit both progestational and antiprogestational activity. Steroids. 1998;63:523-530.
52. Altmae, S., Koel, M., Vosa, U., Adler, P., Suhorutsenko, M., Laisk-Podar, T., Kukushkina, V., Saare, M., Velthut-Meikas, A., Krjutskov, K., Aghajanova, L., Lalitkumar, P.G., Gemzell-Danielsson, K., Giudice, L., Simon, C., Salumets, A., 2017. Meta-signature of human endometrial receptivity: a meta-analysis and validation study of transcriptomic biomarkers. Sci. Rep. 2017;7(1):10077. doi: 10.1038/s41598-017-10098-3.
53. Lira-Albarrán S, Durand M, Barrera D, Vega C, Becerra RC, Diaz L, Garcìa-Quiroz J, Rangel C, Larrea F. A single preovulatory administration of ulipristal acetate affects the decidualization process of the human endometrium during the receptive period of the menstrual cycle. Mol Cell Endocrinol. 2018;476:70-78. https://doi.org/10.1016/j.mce.2018.04.010.
54. Zumoffen C, Gómez-Elíasb MD, Caillea AM, et al. Study of the effect of ulipristal acetate on human sperm ability to interact with tubal tissue and cumulus-oocyte-complexes. Contraception. 2017;95:586-591.
55. Jimenez Guerrero M, Fava M, Baccaro LF, Caille AM , Cuasnicù PS , Horcajadas JA , Cohen DJ , Bahamondes L , Cotàn D, Munuce MJ. Effect of ulipristal acetate on gene expression profile in endometrial cells in culture and in vivo upon post-ovulatory administration in fertile women. Eur J Contracept Reprod Health Care. 2021;6:1-9. doi: 10.1080/13625187.2021.1975270. Online ahead of print.
56. Gomez-Elìas MD, May M, Munuce MJ, Bahamondes L, Cuasnicú PS, Cohen DJ. A single post-ovulatory dose of ulipristal acetate impairs post-fertilization events in mice. Mol Hum Reprod. 2019;25(5):257–264.
57. Li HWR, Lo SST, Ng EHY, Ho PC. Efficacy of ulipristal acetate for emergency contraception and its effect on the subsequent bleeding pattern when administered before or after ovulation. Hum Reprod. 2016;31(6):1200–1207, Advanced Access publication on April 6, 2016 doi:10.1093/humrep/dew055.
58. Shortrede JE, Montt-Guevara MM, Pennacchio G, Finiguerra M, Giannini A, Genazzani AD, Simoncini T. Ulipristal Acetate Interferes With Actin Remodeling Induced by 17β-Estradiol and Progesterone in Human Endometrial Stromal Cells. Front. Endocrinol 2018;9:350. doi: 10.3389/fendo.2018.00350.
59. Berger C, Boggavarupu RN, Menezes J, et al. Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Hum Reprod. 2015;30:800-811.
60. Munuce MJ, Gómez-Elías MD, Caille AM, Bahamondes L, Cuasnicú PS, Cohen D. Mechanisms involved in the contraceptive effects of ulipristal acetate. Reproduction 2020; 159:R139–R149.
61. European Medicines Agency (EMA). Levonorgestrel and Ulipristal remain suitable emergency contraceptives for all women, regardless of bodyweight- EMA/631408/2014. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Emergency_contraceptives_31/WC500176381.pdf.
62. Halpern V, Raymond EG, Lopez LM. Repeated use of pre- and post-coital hormonal contraception for prevention of pregnancy. Cochrane Database of Systematic Reviews. 2014; 9,CD007595. DOI: 10.1002/14651858.CD007595.pub3.
63. Jambrina AM, Rius P, Gascón P, Armelles M, Camps-Bossacoma, Franch A, Rabanal M. Characterization of the Use of Emergency Contraception from Sentinel Pharmacies in a Region of Southern Europe. J Clin Med. 2021;10,2793. https://doi.org/10.3390/jcm10132793.
64. Tsutsui K, Ukena K, Sakamoto H, Okuyama S, Haraguchi S. Biosynthesis mode of action, and functional significance of neurosteroids in the Purkinje cell. Front Endocrinol (Lausanne). 2011;2:61.
65. Schumacher M, Hussain R, Gago N, Oudinet JP, Mattern C, Ghoumari AM. Progesterone synthesis in the nervous system: implications for myelination and myelin repair. Front Neurosci. 2012;6:10.
66. EMA/791062/2017. Available at: https://www.ema.europa.eu/en/documents/ referral/esmya-article-20-procedure-review-started_en.pdf.
67. EMA/355940/2018. Available at, https://www.ema.europa.eu/en/documents/ referral/esmya-article-20-procedure-esmya-new-measures-minimise-riskrare-serious-liver-injury_en.pdf.
68. EMA/455818/2020. Available at: https://www.ema.europa.eu/en/documen ts/referral/ulipristal-acetate-5mg-medicinal-products-article-31-referral-p rac-recommends-revoking-marketing_en.pdf.
69. Yoon EL, Yu JS. Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study. J Clin Endocrinol Metab. 2021; 106(6):1773-1782. doi:10.1210/clinem/dgab081.
70. Meunier L, Meszaros M, Pageaux GP, Delay JM, Herrero A, Pinzani V, et al. Case report. Acute liver failure requiring transplantation caused by ulipristal acetate. Clin Res Hepatol Gastroenterol. 2020;44(3):e45-e49.
71. Pohl O, Osterloh I, Gotteland JP. Ulipristal acetate – safety and pharmacokinetics following multiple doses of 10–50 mg per day. J Clin Pharm Ther. 2013;38:314–320.
72. Gatti M, Poluzzi E, De Ponti F, Raschi E. Liver injury with ulipristal acetate: exploring the underlying pharmacological basis. Drug Saf. 2020;43(12):1277–1285.
73. Small B, Millard CEF, Kisanga EP, Burman A, Anam A, Flannery C, Al-Hendy A, Whirledge S. The Selective Progesterone Receptor Modulator Ulipristal Acetate Inhibits the Activity of the Glucocorticoid Receptor. J Clin Endocrinol Metab. 2020;105:716–734.
74. Hussain S, Haidar A, Bloom RE, Zayouna N, Piper MH, Jafri SM. Bicalutamide-induced hepatotoxicity: a rare adverse effect. Am J Case Rep. 2014;15:266-270.
75. Bruni V, Peruzzi E, Dei M, et al. Hepatotoxicity with low- and ultralowdose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril. 2012;98(4):1047-1052. doi: 10.1016/j.fertnstert.2012.06.018.
76. Rosenthal SA, Linstadt DE, Leibenhaut MH, et al. Flutamide associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology. 1996;199(2):451-455.
77. Raschi E, De Ponti F. Strategies for early prediction and timely recognition of drug-induced liver injury: the case of cyclin- dependent kinase 4/6 inhibitors. Front Pharmacol. 2019;10:1235.
78. Middelkoop MA, de Lange ME, Clark TJ , Mol BWJ, Bet PM, Huirne JAF, Hehenkamp WJK. Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids. Hum Reprod. 2022; .37(5):884–894. Advance Access Publication on February 10, 2022. https://doi.org/10.1093/humrep/deac009
79. Yokoe T, Audhya T, Brown C, Hutchinson B, Passarelli J, Hollander CS. Corticotropin-releasing factor levels in the peripheral plasma and hypothalamus of the rat vary in parallel with changes in the pituitary-adrenal axis. Endocrinology. 1988;123(3):1348–1354. doi:10.1210/clinem/dgz139 https://academic.oup.com/jcem 733.
80. Kageyama K, Akimoto K, Yamagata S, et al. Dexamethasone stimulates the expression of ghrelin and its receptor in rat hypothalamic 4B cells. Regul Pept. 2012;174(1-3):12–17.
81. Calogero AE, Burrello N, Bosboom AM, Garofalo MR, Weber RF, D’Agata R. Glucocorticoids inhibit gonadotropin releasing hormone by acting directly at the hypothalamic level. J Endocrinol Invest. 1999;22(9):666–670.
82. Taylor AD, Cowell AM, Flower RJ, Buckingham JC. Dexamethasone suppresses the release of prolactin from the rat anterior pituitary gland by lipocortin 1 dependent and independent mechanisms. Neuroendocrinology. 1995;62(5).530-542. doi: 10.1159/000127044.
83. Theis V, Theiss C. Progesterone Effects in the Nervous System. Anat Rec. 2019;302:1276-1286.
84. Mozzanega B. Ulipristal Acetate and liver-injuries: while Esmya is revoked, EllaOne is allowed in repeated self-administrations possibly exceeding UPA toxic-dosing with Esmya. J Hepatol. 2021;74:750-751; S0168-8278(20)33828-9. doi: 10.1016/j.jhep.2020.11.041. Online Nov 30 ahead of print.
85. Westhoff CL, Archer DF, Barnhart K, Darney P, Gilliame M, Jensen J, Nelsong A, Teal S, Thomas M , Huj J, Brown J , Blithe DL. Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day Ulipristal acetate regimens. Contraception. 2022;112:54-60.
86. Chabbert-Buffet N, Pintiaux-Kairis A, Bouchard PVA2914 Study Group. Effects of the progesterone receptor modulator VA2914 in a continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J Clin Endocrin Metab. 2007;92(9):3582–9.
87. Brache V, Sitruk-Ware R, Williams A, Blithe D, Croxatto H, Kumar N, et al. Effects of a novel estrogen-free, progesterone receptor modulator contraceptive vaginal ring on inhibition of ovulation, bleeding patterns and endometrium in normal women. Contraception. 2012;85:480–8.
88. Huang Y, Jensen JT, Brache V, Cochon L, Williams A, Miranda M, et al. A randomized study on pharmacodynamic effects of vaginal rings delivering the progesterone receptor modulator ulipristal acetate: Research for a novel estrogen-free method of contraception. Contraception. 2014; 90(6):565-574.